NASDAQ:CLBS - Caladrius Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.15 -0.05 (-1.19 %) (As of 02/21/2019 04:31 AM ET)Previous Close$4.20Today's Range$4.14 - $4.2052-Week Range$3.05 - $11.65Volume39,800 shsAverage Volume27,524 shsMarket Capitalization$40.84 millionP/E Ratio-2.33Dividend YieldN/ABeta1.89 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY. Receive CLBS News and Ratings via Email Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLBS Previous Symbol CUSIPN/A Webwww.caladrius.com Phone908-842-0100Debt Debt-to-Equity RatioN/A Current Ratio9.66 Quick Ratio9.66Price-To-Earnings Trailing P/E Ratio-2.33 Forward P/E Ratio-2.37 P/E GrowthN/A Sales & Book Value Annual Sales$35.28 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$5.30 per share Price / Book0.78Profitability EPS (Most Recent Fiscal Year)($1.78) Net Income$22.97 million Net MarginsN/A Return on Equity-36.56% Return on Assets-29.87%Miscellaneous Employees22 Outstanding Shares9,842,000Market Cap$40.84 million OptionableOptionable Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions What is Caladrius Biosciences' stock symbol? Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS." How were Caladrius Biosciences' earnings last quarter? Caladrius Biosciences Inc (NASDAQ:CLBS) announced its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.56) by $0.20. View Caladrius Biosciences' Earnings History. When is Caladrius Biosciences' next earnings date? Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for Caladrius Biosciences. What price target have analysts set for CLBS? 2 analysts have issued twelve-month price objectives for Caladrius Biosciences' stock. Their predictions range from $7.00 to $18.50. On average, they anticipate Caladrius Biosciences' share price to reach $12.75 in the next twelve months. This suggests a possible upside of 207.2% from the stock's current price. View Analyst Price Targets for Caladrius Biosciences. What is the consensus analysts' recommendation for Caladrius Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Caladrius Biosciences. What are Wall Street analysts saying about Caladrius Biosciences stock? Here are some recent quotes from research analysts about Caladrius Biosciences stock: 1. According to Zacks Investment Research, "Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. " (2/11/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement; only need a little to be potentially quite meaningful. We reiterage our Buy rating and $18.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. As part of our valuation projections, we make the following assumptions, which we also believe provide additional levels of conservatism to our projections." (1/24/2019) Has Caladrius Biosciences been receiving favorable news coverage? Headlines about CLBS stock have been trending somewhat positive on Thursday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Caladrius Biosciences earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. Who are some of Caladrius Biosciences' key competitors? Some companies that are related to Caladrius Biosciences include MYnd Analytics (MYND), Pacific Health Care Organization (PFHO), BioRestorative Therapies (BRTX), American Caresource (GNOW) and Hooper Holmes (HPHW). Who are Caladrius Biosciences' key executives? Caladrius Biosciences' management team includes the folowing people: David J. Mazzo, President, Chief Executive Officer & DirectorJoseph Talamo, Chief Financial Officer & Senior Vice PresidentDouglas W. Losordo, Chief Medical Officer & SVP-Regulatory AffairsGreg Berkin, Vice President-Information TechnologyJohn D. Menditto, Executive Director-Investor Relations How do I buy shares of Caladrius Biosciences? Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Caladrius Biosciences' stock price today? One share of CLBS stock can currently be purchased for approximately $4.15. How big of a company is Caladrius Biosciences? Caladrius Biosciences has a market capitalization of $40.84 million and generates $35.28 million in revenue each year. The biotechnology company earns $22.97 million in net income (profit) each year or ($1.78) on an earnings per share basis. Caladrius Biosciences employs 22 workers across the globe. What is Caladrius Biosciences' official website? The official website for Caladrius Biosciences is http://www.caladrius.com. How can I contact Caladrius Biosciences? Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected] MarketBeat Community Rating for Caladrius Biosciences (NASDAQ CLBS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 258 (Vote Outperform)Underperform Votes: 209 (Vote Underperform)Total Votes: 467MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: Why is the ex-dividend date different from the record date?